Journal article
Update on C3 Glomerulopathy
Advances in kidney disease and health (Online), Vol.31(3), pp.223-233
05/2024
DOI: 10.1053/j.akdh.2024.05.002
Abstract
C3 glomerulopathy (C3G) is a rare disorder marked by deposition of C3 in the glomerulus, resulting in damage to the glomerular filtration unit and presenting with features of the nephritic and nephrotic syndromes. Fundamentally, C3G is caused by dysregulation of the alternative pathway of the complement cascade, either due to genetic variants or acquired humoral factors. Despite significant advances in recent years in the understanding of the underlying mechanisms and culprit lesions that result in the development of C3G, treatment options remain severely limited, and the prognosis is often poor. Fortunately, a number of anticomplement therapies are emerging from the drug development pipeline, with several in late-stage testing in patients with C3G, and there is hope that we will soon have more targeted options for managing patients with this devastating disease. In this review, we provide an overview of C3G, as well as summarizing the evidence for current treatments and detailing the clinical trials that are currently underway.
Details
- Title: Subtitle
- Update on C3 Glomerulopathy
- Creators
- Benjamin Wooden - Columbia UniversityCarla M. Nester - University of IowaAndrew S. Bomback - Columbia University
- Resource Type
- Journal article
- Publication Details
- Advances in kidney disease and health (Online), Vol.31(3), pp.223-233
- Publisher
- Elsevier Inc
- DOI
- 10.1053/j.akdh.2024.05.002
- ISSN
- 2949-8139
- eISSN
- 2949-8139
- Language
- English
- Date published
- 05/2024
- Academic Unit
- Internal Medicine; Stead Family Department of Pediatrics; Nephrology, Dialysis and Transplantation
- Record Identifier
- 9984656558302771
Metrics
2 Record Views